Kite Pharma, Inc.

Galapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w

German multinational Miltenyi Biotec’s senior leadership sees significant opportunities for India in the cell and gene therapy space if it can get things right in terms of shaping the regulatory frame

England’s health technology assessment institute, NICE, has reversed its rejection of the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating relapsed or refractory large B-cell lympho

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do